MorphoSys to Present at Four Investor Conferences in May

MorphoSys to Present at Four Investor Conferences in May 
MARTINSRIED, GERMANY and MUNICH, GERMANY -- (Marketwired) -- 05/08/13
--  MorphoSys AG / MorphoSys to Present at Four Investor Conferences
in May . Processed and transmitted by Thomson Reuters ONE. The issuer
is solely responsible for the content of this announcement. 
The  management of MorphoSys AG (FSE: MOR; Prime Standard Segment,
TecDAX) will
present at four upcoming international investor
conferences: 


 
Credit Suisse Antibody Day
Date: May 10, 2013, 09:00am EDT (03:00pm CEST, 02:00pm BST)
Venue: New York, USA
Participants: Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG,
Dr.
Claudia Gutjahr-Loeser, Head of Corporate Communications & Investor
Relations
 
Deutsche Bank German, Swiss & Austrian Conference 2013
Date: May 14, 2013
Venue: Frankfurt, Germany
Participants: Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG
 
Helvea's EU Healthcare Tour
Date: May 14, 2013
Venue: Frankfurt, Germany
Participants: Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG
 
BioEquity Europe 2013
Date: May 22, 2013, 05:00pm CEST (11:00am EDT, 04:00pm BST)
Venue: Stockholm, Sweden
Participants: Jens Holstein, Chief Financial Officer of MorphoSys AG, Dr.
Claudia Gutjahr-Loeser, Head of Corporate Communications & Investor
Relations

  
The  PDF version of the presentation  will be provided at
www.morphosys.com. The link to the webcast will be filed under
www.morphosys.com/conference-calls. 
About MorphoSys: 
MorphoSys developed HuCAL, the most successful antibody library
technology in
the pharmaceutical industry. By successfully applying
this and other patented
technologies, MorphoSys has become a leader
in the field of therapeutic antibodies, one of the fastest-growing
drug classes in human healthcare. 
Together with its pharmaceutical partners, MorphoSys has built a
therapeutic
pipeline of more than 70 human antibody drug candidates
for the treatment of
cancer, rheumatoid arthritis, and Alzheimer's
disease, to name just a few. With
its ongoing commitment to new
antibody technology and drug development, MorphoSys is focused on
making the healthcare products of tomorrow. MorphoSys is listed on
the Frankfurt Stock Exchange under the symbol MOR. For regular
updates
about MorphoSys, visit http://www.morphosys.com. 
HuCAL(R),  HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R),
RapMAT(R), arYla(R), Ylanthia(R)  and  100 billion  high 
potentials(R)  are registered trademarks of MorphoSys AG. 
Slonomics(R)  is  a  registered  trademark  of  Sloning 
BioTechnology GmbH,  a subsidiary of MorphoSys AG. 
This  communication contains  certain forward-looking  statements
concerning the MorphoSys  group of  companies. The  forward-looking
statements contained herein
represent  the judgment of MorphoSys as
of  the date of this release and involve
risks  and  uncertainties. 
Should  actual  conditions differ from the Company's
assumptions, 
actual  results  and  actions  may  differ from those
anticipated.
MorphoSys  does not intend to update  any of these
forward-looking statements as far as the wording of the relevant press
release is concerned. 
Conference Announcement (PDF):
http://hugin.info/130295/R/1700388/561265.pdf 
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants
that: 
(i) the releases contained herein are protected by copyright and    
other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and     
originality of the information contained therein. 
Source: MorphoSys AG via Thomson Reuters ONE 
[HUG#1700388] 
For more information, please contact: 
MorphoSys AG
Dr. Claudia Gutjahr-Loser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122 
Mario Brkulj
Associate Director Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454 
Alexandra Goller
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332 
investors@morphosys.com
 
 
Press spacebar to pause and continue. Press esc to stop.